Our People
and Culture

Bringing together diverse experiences, our people are the cornerstone of Sunovion and shape our culture while advancing our success. With their combined talent and dedication, they align, collaborate and win as one team.

Three coworkers laughing with one of their peers.

Diversity & Inclusion

Sunovion is committed to embracing diversity and inclusion in everything we do. Our team brings a wide variety of experiences and approaches to work, allowing us to offer our patients the most innovative and effective solutions.

Teammates in a meeting around a table and laughing together.

Social Responsibility

Because we believe in supporting the communities where we live and work, we partner with local organizations who share our passion. Far more than a commitment, we consider it our responsibility to make our world stronger and healthier.

A woman supporting her community by providing local support on a farm.

Our History

Over the course of Sunovion's history, we have delivered clinical advances and new treatment options, and led advocacy and educational initiatives with cross-sector coalitions focused on the advancement of research, innovation and improvements in healthcare.



  • Health Canada approves Kynmobi (apomorphine hydrochloride) soluble film for the treatment of Parkinson’s disease OFF episodes.
  • U.S. approves Kynmobi (apomorphine hydrochloride) sublingual film for the treatment of OFF episodes associated with Parkinson's disease (PD).


  • Sunovion Hands On! Annual Community Service Program contributes more than 30,000 employee volunteer hours in 439 projects in eight years to community organizations and relief efforts


  • Sunovion Hands On! Community Service Program contributes 25,000+ volunteer hours in 415+ projects in seven years
  • Health Canada Approves of Aptiom® (eslicarbazepine acetate) as adjunctive therapy for the treatment of partial-onset seizures in adolescents above six years of age and as a monotherapy for adults with epilepsy


  • Receives FDA approval for Latuda® to treat adolescents with schizophrenia


  • Sunovion ranks as second-fastest growing pharmaceutical company*
  • Receives Corporate Responsibility Award, United Way of Tri-County, 2016
  • Complete acquisition of Cynapsus Therapeutics and its product candidate


  • Honoured with The JED Foundation Corporate Leadership Award for leadership in mental health
  • Won SCRIP Award for Management Team of the Year


  • Health Canada approves Aptiom® as once-daily adjunctive treatment


  • FDA approves Latuda® as monotherapy and adjunctive therapy in adults with bipolar depression
  • Receives FDA approval of Aptiom® (eslicarbazepine acetate) as adjunctive treatment of partial-onset seizures


  • Complete acquisition of Elevation Pharmaceuticals
  • Launches annual Hands On! community service program to give back where employees live and work
  • Health Canada approves Latuda® for schizophrenia in adults


  • Announces partnership with CARE Inc., an international humanitarian agency, to help improve the health and lives of those in need


  • Sunovion is established (October 2010) following the integration of Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc., former U.S. operations of Sunovion’s parent company Sumitomo Dainippon Pharma Co., Ltd.
  • The FDA approves Latuda® (lurasidone HCl) for the treatment of adult patients with schizophrenia